It belongs to the improved product generation of the well-known high-tech effect pigments and stands out due to an attractive bluish red and very intense glitter. The company assumes no duty to update the information to reflect subsequent developments. . These figures refer to all people directly employed by Merck and therefore may deviate from figures in the financial section of this report. Journalists are invited to monitor the call by dialing 706 758-9928 or 800 399-7917. Employees must demonstrate a commitment to Client focus, People focus, Trust and Teamwork focus, Excellence focus and Respect and Integrity focus. The Life Science Research Solutions business unit serves customers focused on identifying and developing new medicines.
An important growth driver for our Biopharma business is our portfolio of fertility products that help couples conceive a child, ranging from drugs to technologies. In order to support our business expansion in Asia, we opened a new research and application center at our site in Kaohsiung, Taiwan. Particularly strong growth was generated by materials for dielectric insulating layers and metal layers deposited from the gas phase used for advanced processors and latest-generation storage chips. The capacities at the application laboratory in Korea were doubled in 2017. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. Investors are invited to a live audio webcast of Merck's second-quarter earnings conference call today at 8:00 a.
This focus on innovation and execution will drive long-term shareholder value. With our three business sectors Healthcare, Life Science and Performance Materials, we are not only successful, but also improve the lives of patients, customers and partners all over the world. Our divestment of the Biosimilars business to Fresenius closed on August 31. China is one of the fastest-growing markets for our pigments and cosmetics businesses. The company assumes no duty to update the information to reflect subsequent developments. The authoritative German versions of these financial statements are filed with the German Federal Gazette Bundesanzeiger and can be accessed at 2 Reporting principles The consolidated financial statements of the Merck Group have been prepared in accordance with consistent accounting policies and in euros, the reporting currency.
Includes expenses for the amortization of intangible assets and amortization of purchase accounting adjustments to inventories recognized as a result of mergers and acquisitions, as well as intangible asset impairment charges. In 2017, we opened a new application laboratory in Shanghai, China. As of June 30, 2012, Merck had approximately 84,000 employees worldwide. Our aim is to make research and biomanufacturing easier, faster and more successful. After successfully orchestrating the largest integration in the history of Merck, the Life Science business sector redesigned its organizational structure in the second quarter of 2017 to capture growth opportunities even more nimbly and to align the entire organization to optimally contribute to, and capitalize on the strength of the Merck Group. On September 5, we announced that we are preparing strategic options for our Consumer Health business, including a potential full or partial sale of the business as well as strategic partnerships. Merck continues to expect full-year 2012 revenues to be at or near 2011 levels on a constant currency basis.
The figures presented in this combined management report have been rounded. Occupancy Planning and Move Management The Merck account Occupancy Planning team achieved a Bronze Supernova certification in 2013 and is in the final review for receiving another Supernova award based on their accomplishments in 2014. With a market share above 40% and double-digit sales growth, Euthyrox ® active ingredient levothyroxine is the worldwide market leader for treating hypothyroidism, a disease with high prevalence but low diagnosis in most emerging markets. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. Developed cafe plans for K1 headquarters building.
Our Fertility Technologies business continues to broaden its footprint. Strategic realignment In 2018, we want to focus even more strongly on the needs of our customers and markets. People are becoming more health-conscious and looking after their own physical well-being. The new center gives customers access to a complete food-safety workflow, from raw materials testing to finished-product safety testing, to help find, correct and prevent hazards within the food supply chain. We enter 2018 with strong operating momentum, based on our key pillars of growth that will enable us to deliver on our mission of improving patients lives. In addition, Allergopharma provides individual allergen extracts on a named patient basis, which are needed to treat less frequent allergies. The acquisition strengthens our ability to help customers protect the global food supply by providing an extensive portfolio of state-of-the-art testing technology.
We were awarded for our eHealth ecosystem designed to improve treatment outcomes by working with patients, carers and healthcare professionals. Back in 2016, we launched the Displaying Futures Award to promote young entrepreneurs and researchers. Accommodation for applicants with disabilities is available as part of the application and recruitment process. In 2016, we implemented a centralized initiative to manage all customer acquisition channels and scaled search advertising to include more than two million active keywords to drive increased web traffic to the content customers are seeking. The aim is to emotionalize these over-the-counter and food supplement brands so that they become irresistible love brands in the eyes of our consumers and customers alike. In addition, Bavencio ® was approved for the treatment of patients with urothelial carcinoma in Israel in late January 2018. In Life Science, we conduct research for researchers, providing scientists with laboratory materials, technologies and services.
We see steadily increasing demand in growth markets fueling sales. We serve customers in academia, biotech and pharma — helping them to deliver the promise of their work better, faster and safer. In 2017, we continued to optimize our web channel and streamline the customer experience, resulting in increased user sessions and revenue. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. The Life Science business sector reinforced its commitment to food safety with the acquisition of BioControl Systems Inc.
This may lead to individual values not adding up to the totals presented. The decrease was primarily due to ongoing productivity measures. The slight downward trend was attributed to the Merck site closures and related staffing moves across the Merck portfolio. This includes more than 200,000 products and services, including molecular platforms, protein and pathway technologies, biochemicals, materials science and cell culture workflow tools. Natrix is known for its unique technology platform, which delivers high productivity and impurity removal in a single-use format.
In regard to the strategic alliance with Pfizer Inc. For its innovative 3D effect printing technology, Merck entered into a strategic partnership with Schmid Rhyner of Switzerland. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date. Our effect pigments are primarily used in automotive and industrial coatings, plastics, printing applications, cosmetics and some foods, in order to give products a unique luster. Our 300,000 products range from lab water systems to genome-editing tools, antibodies and cell lines, as well as end-to-end bioprocessing systems to support the manufacturing needs of both emerging biotech and large pharma companies. The figures presented in this combined management report have been rounded.